Savara Inc SEC filings SVRA
Savara Inc has 1,000 filings in SEC EDGAR's recent list, going back to Jul 22, 2009. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jun 8, 2026 (officer or director change, bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 4, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2026 | Jun 4, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 6, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2024 | Jun 6, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 8, 2023 |
| DEFA14A | Additional proxy material | Apr 19, 2022 | — |
| DEF 14A | Proxy statement | Apr 19, 2022 | Jun 2, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 10, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2021 | Jun 10, 2021 |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEFA14A | Additional proxy material | Apr 15, 2020 | — |
| DEF 14A | Proxy statement | Apr 15, 2020 | May 27, 2020 |
| DEFA14A | Additional proxy material | Apr 15, 2019 | — |
| DEF 14A | Proxy statement | Apr 15, 2019 | May 29, 2019 |
| DEFA14A | Additional proxy material | Apr 23, 2018 | — |
| DEF 14A | Proxy statement | Apr 23, 2018 | Jun 4, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2018 | Jun 4, 2018 |
| DEFA14A | Additional proxy material | Sep 13, 2017 | — |
| DEF 14A | Proxy statement | Sep 13, 2017 | Oct 25, 2017 |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 15, 2016 |
| DEFA14A | Additional proxy material | Apr 29, 2015 | — |
| DEF 14A | Proxy statement | Apr 29, 2015 | Jun 11, 2015 |
| DEFA14A | Additional proxy material | Apr 29, 2014 | — |
| DEF 14A | Proxy statement | Apr 29, 2014 | Jun 19, 2014 |
| DEFA14A | Additional proxy material | Apr 29, 2013 | — |
| DEF 14A | Proxy statement | Apr 29, 2013 | Jun 19, 2013 |
| DEF 14A | Proxy statement | Apr 27, 2012 | Jun 20, 2012 |
| DEF 14A | Proxy statement | Apr 28, 2011 | Jun 15, 2011 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2011 | Jun 15, 2011 |
| DEFA14A | Additional proxy material | Apr 11, 2011 | — |
| DEF 14A | Proxy statement | May 27, 2010 | Jun 30, 2010 |
| DEF 14A | Proxy statement | Jul 23, 2009 | Aug 25, 2009 |
Showing 39 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1160308
- Former names
- Mast Therapeutics, Inc. (until Apr 25, 2017); ADVENTRX PHARMACEUTICALS INC (until Mar 1, 2013); BIOKEYS PHARMACEUTICALS INC (until May 15, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.